Moore, K. N., Secord, A. A., Geller, M., Miller, D. S., Cloven, N. G., Fleming, G. F., … Monk, B. J. (2018). QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. In Ann Oncol (Vol. 29 Suppl 8, p. viii337). England. https://doi.org/10.1093/annonc/mdy285.152

Moore, K. N., A. A. Secord, M. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, A. E. Wahner Hendrickson, et al. “QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset.” In Ann Oncol, 29 Suppl 8:viii337, 2018. https://doi.org/10.1093/annonc/mdy285.152.

Moore KN, Secord AA, Geller M, Miller DS, Cloven NG, Fleming GF, et al. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. In: Ann Oncol. 2018. p. viii337.

Moore, K. N., et al. “QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset.” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii337. Pubmed, doi:10.1093/annonc/mdy285.152.

Moore KN, Secord AA, Geller M, Miller DS, Cloven NG, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza A, Cristea M, Berek JS, Chan JK, Rimel BJ, Li Y, Luptakova K, Clark R, Matulonis UA, Monk BJ. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. Ann Oncol. 2018. p. viii337.